Home World News First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in... World News First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 335 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Woman Who Lost Husband to Male Breast Cancer Goes on Road... September 16, 2021 Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for... May 19, 2026 Returning to Dental Care August 24, 2020 EMA Recommends Extension of Therapeutic Indications for Tremelimumab July 20, 2023 Load more HOT NEWS Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer EMA Recommends Extension of Indications for Sugemalimab Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer ¿El azúcar provoca cáncer?
